微生物转化法制备普瑞巴林手性中间体
|
摘要
普瑞巴林(Pregabalin),(S)-3-氨甲基-5-甲基己酸,是一种用于抗神经痛和癫痫症的辅助治疗的手性药物,其国际市场需求呈现较快增长之势。开展生物催化法制备普瑞巴林的研究,筛选拆分制备普瑞巴林的微生物,具有重要的应用前景和价值。
(S)-2-羧乙基-3-氰基-5-甲基己酸乙酯((S)-CCMAE)是合成普瑞巴林的关键手性中间体。本文首先以外消旋体2-羧乙基-3-氰基-5-甲基己酸乙酯(CCMAE)为底物,从土壤中筛选得到一株具有自主知识产权的能够对映选择性水解(R)-CCMAE的假单胞菌(Pseudomonas) CGMCC No.4184。对其产酶条件及培养基进行了优化,使酶活从15.92 U/L提高到33.43 U/L。随后对假单胞菌CGMCCNo.4184静息细胞水解拆分底物的反应条件进行了研究,确定了较优反应条件为：30～35℃,pH 7.5-8.5。并成功利用微生物静息细胞转化法制备了ee值达99.8%的(S)-CCMAE,这与目前报道的生物拆分工艺均有所不同。研究还发现Tween-80和TritonX-100可明显提高对映选择率E值和酶活。最后利用海藻酸钠-PVA复合载体法制备了假单胞菌CGMCC No.4184的固定化细胞,对其技术参数和反应条件作了优化,并利用所制得的固定化细胞制备ee值99%以上的(S)-CCMAE。该固定化细胞能够较好地进行重复利用。
本研究中筛选获得的高选择性R型水解酶可能是一种新酶,后续的基因克隆和表达、酶学性质研究工作正在进行中,为进一步改善酶的催化性能和拓展应用范围打下了良好的基础。
Pregabalin, (S)-3-aminomethyl-5-methylhexanioc acid, is the 3-isobutyl substituent of GABA and a chiral drug that can be used as an adjuvant therapy for antineuralgic and anti-Epilepsy. The applications of pregabalin have grown markedly in recent years and are likely to expand in the coming years. Therefore, the studies on the preparation methods of optically active pregabalin and screening of biocatalysts are very important both for the knowledge on biocatalytic mechanism and its application.
(S)-2-carboxyethyl-3-Cyano-5-methylhexanoic acid ethylester ((S)-CCMAE) is an important chiral intermediate of pregabalin. In this paper, firstly, using racemic CCMAE as the substrate, Pseudomonas sp. CGMCC No.4184 was isolated which can enantioselectively hydrolyze (R)-CCMAE. By optimization of the fermentation medium and the reaction conditions, the enzyme activity increased from 15.92 U/L to 33.43 U/L. Secondly, the resolution conditions by resting cells of Pseudomonas CGMCC No.4184 was investigated, and the results showed that the optimal temperature was 30-35℃and pH 7.5-8.5. After optimization, (S)-CCMAE were successfully prepared with ees of 99.8%. This method was different from all reportorial biotransformation process. Tween-80 and TritonX-100 were found to increase the enantioselectivity (E value) and enzyme activitiy. Finally, Sodium alginate-PVA-CaCl2 method was used to prepare the immobilized cells of Pseudomonas CGMCC No.4184. By optimization of the parameters and the reaction conditions, (S)-CCMAE (ees over 99%) were prepared and the immobilized cells have got good operational stability.
In this study, the isolated hydrolase that has the high R-selectivity may be a noval enzyme. In order to improve the catalysis performance and exploit the application of this R-enantioselective hydrolyse, the study on gene cloning-expression and the enzymology characters would be carried out soon.
(S)-2-羧乙基-3-氰基-5-甲基己酸乙酯((S)-CCMAE)是合成普瑞巴林的关键手性中间体。本文首先以外消旋体2-羧乙基-3-氰基-5-甲基己酸乙酯(CCMAE)为底物,从土壤中筛选得到一株具有自主知识产权的能够对映选择性水解(R)-CCMAE的假单胞菌(Pseudomonas) CGMCC No.4184。对其产酶条件及培养基进行了优化,使酶活从15.92 U/L提高到33.43 U/L。随后对假单胞菌CGMCCNo.4184静息细胞水解拆分底物的反应条件进行了研究,确定了较优反应条件为：30～35℃,pH 7.5-8.5。并成功利用微生物静息细胞转化法制备了ee值达99.8%的(S)-CCMAE,这与目前报道的生物拆分工艺均有所不同。研究还发现Tween-80和TritonX-100可明显提高对映选择率E值和酶活。最后利用海藻酸钠-PVA复合载体法制备了假单胞菌CGMCC No.4184的固定化细胞,对其技术参数和反应条件作了优化,并利用所制得的固定化细胞制备ee值99%以上的(S)-CCMAE。该固定化细胞能够较好地进行重复利用。
本研究中筛选获得的高选择性R型水解酶可能是一种新酶,后续的基因克隆和表达、酶学性质研究工作正在进行中,为进一步改善酶的催化性能和拓展应用范围打下了良好的基础。
Pregabalin, (S)-3-aminomethyl-5-methylhexanioc acid, is the 3-isobutyl substituent of GABA and a chiral drug that can be used as an adjuvant therapy for antineuralgic and anti-Epilepsy. The applications of pregabalin have grown markedly in recent years and are likely to expand in the coming years. Therefore, the studies on the preparation methods of optically active pregabalin and screening of biocatalysts are very important both for the knowledge on biocatalytic mechanism and its application.
(S)-2-carboxyethyl-3-Cyano-5-methylhexanoic acid ethylester ((S)-CCMAE) is an important chiral intermediate of pregabalin. In this paper, firstly, using racemic CCMAE as the substrate, Pseudomonas sp. CGMCC No.4184 was isolated which can enantioselectively hydrolyze (R)-CCMAE. By optimization of the fermentation medium and the reaction conditions, the enzyme activity increased from 15.92 U/L to 33.43 U/L. Secondly, the resolution conditions by resting cells of Pseudomonas CGMCC No.4184 was investigated, and the results showed that the optimal temperature was 30-35℃and pH 7.5-8.5. After optimization, (S)-CCMAE were successfully prepared with ees of 99.8%. This method was different from all reportorial biotransformation process. Tween-80 and TritonX-100 were found to increase the enantioselectivity (E value) and enzyme activitiy. Finally, Sodium alginate-PVA-CaCl2 method was used to prepare the immobilized cells of Pseudomonas CGMCC No.4184. By optimization of the parameters and the reaction conditions, (S)-CCMAE (ees over 99%) were prepared and the immobilized cells have got good operational stability.
In this study, the isolated hydrolase that has the high R-selectivity may be a noval enzyme. In order to improve the catalysis performance and exploit the application of this R-enantioselective hydrolyse, the study on gene cloning-expression and the enzymology characters would be carried out soon.
引文
[1]Andruszkiewicz R, Silverman RB. A Convenient synthesis of 3-alkyl-4-aminobutanoic acids. Synthesis 1989;(12):953-955.
[2]Bryans JS, Wustrow DJ.3-substituted GABA analogs with central nervous system activity:a review. Med Res Rev 1999; 19(2):149-177.
[3]Pellock JM. Treatment of epilepsy in the new millennium. Pharmacotherapy 2000; 20(8 Pt2):129S-138S.
[4]Singh D, Kennedy DH. The use of gabapentin for the treatment of postherpetic neuralgia. Clin Ther 2003;25(3):852-889.
[5]陈敖,张建军.普瑞巴林的合成.中国医药工业杂志2004；35(4)：195-196.
[6]陈敖,张建军.新药普瑞巴林的合成.精细与专用化学品2005；13(10)：14-17.
[7]李晓东,须眉GABA受体激活剂：普瑞巴林(pregabalin)世界临床药物2006；27(3)：186-187.
[8]陈宝泉,李彩文,史艳萍,卢学磊,麻静.普瑞巴林的药理作用及临床评价.中国新药与临床杂志2010；29(1)：11-14.
[9]崔露阳.抗癫痫药物市场格局浅析.世界临床药物2005；26(3)：188-191.
[10]江正祥.抗癫痫药物市场发展趋势.世界临床药物2010；31(8)：510-513.
[11]伍光辉,潘天伟.抗癫痫药物治疗精神病研究进展Internal Medicine China 2008; 3(6):924-926.
[12]洪刚,章江生,王琳辉.抗癫痫药物研究进展.中国临床药理学与治疗学2005；10(11)：1201-1209.
[13]Warner G, Figgitt DP. Pregabalin-As adjunctive treatment of partial seizures. Cns Drugs 2005; 19(3):265-272.
[14]Simko J, Horacek J, Waberzinek G. Severe hypothyroidism as a complication of anticonvulsant treatment. Epilepsia 2004; 45(3):292-293.
[15]Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine 1999; 159(16):1931-1937.
[16]Huang CW, Huang CC. Wu SN. The opening effect of pregabalin on ATP-sensitive potassium channels in differentiated hippocampal neuron-derived HI9-7 cells. Epilepsia 2006; 47(4):720-726.
[17]Stahl SM. Anticonvulsants as anxiolytics, part 2:pregabalin and gabapentin as α2δ ligands at voltage-gated calcium channels. Clin Psychiatry 2004; 65(4):460-461.
[18]Joshi I, Taylor CP. Pregabalin action at a model synase; binding to presynaptic calcium channel alpha2-delta subunit reduces neurotransmission in mice. Eur J Pharmacol 2006; 553(1-3):82-88.
[19]Belliotti TR. Capiris T, Ekhato IV, al. e. Structure-activity relationships of pregabalin and analogues that target the alpha2-delta protein. J Med Chem 2005; 48(7):2294-2307.
[20]Galluzzi KE. Managing neuropathic pain. J Am Osteopath Assoc 2007; 107(10 Suppl 60):ES39-ES48.
[21]Aiello EC. Thomson A. vera 1M. ai e. Cost-effectiveness of pregabalin and other acid-on amiepileptic drug therapies in. patiems with refracton partial epilepsy in Aroentina. vaiue Health 200-:10:89.
[22]Herranz JL, Argumosa A. Rejas J, al e. Model-based evaluation of the cost-effectiveness of pregabalin. levetiracetam and generic gabapentin versus standard therapy as an add-on antiepileptic therapy in patients with refractory epilepsy:a Spanish perspective. Epilepsia 2005; 46(Suppl 6):S115-S116.
[23]Rosenstock J, Michael TB, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy:a double-blind, placebo-controlled trial. Pain 2004; 110(3):628-638.
[24]陈志青,徐俊冕.抗癫痫药物用于焦虑障碍治疗的评价.世界临床药物2005；26(12)：747-753.
[25]Suljic E. Alajbegovic A, Kucukalic A, Loncarevic N. [Comorbid depression in patients with epilepsy treated with single and multiple drug therapy]. Med Arh 2003; 57(5-6 Suppl 1):45-46.
[26]Leppik LE, Bergey GK, Ramsay RE, et al. Advances in antiepileptic drug treatments-A rational basis for selecting drugs for older patients with epilepsy. Geriatrics 2004; 59(12):14-+.
[27]赵倩,李讳亮,肖学凤.治疗神经性疼痛新药-普瑞巴林.天津药学2007;19(12)：53-55.
[28]Evans DA, Ennis MD, Mathre DJ. Asymmetric alkylation reactions of chiral imide enolates-A Practical approach to the enantioselective synthesis of alpha-substituted carboxylic-acid derivatives. J Am Chem Soc 1982; 104(6): 1737-1739.
[29]Yuen PW, Kanter GD, Taylor CP, Vartanian MG. Enantioselective synthesis of PD144723-A Potent stereospecific anticonvulsant. Bioorganic & Medicinal Chemistry Letters 1994; 4(6):823-826.
[30]Hoekstra MS, Sobieray DM, Schwindt MA, et al. Chemical development of CI-1008, an enantiomerically pure anticonvulsant. Organic Process Research & Development 1997; 1(1):26-38.
[31]Sammis GM, Jacobsen EN. Highly enantioselective, catalytic conjugate addition of cyanide to alpha,beta-unsaturated Imides. J Am Chem Soc 2003; 125(15): 4442-4443.
[32]Burk MJ, de Koning PD, Grote TM, et al. An enantioselective synthesis of (S)-(+)-3-aminomethyl-5-methylhexanoic acid via asymmetric hydrogenation. Journal of Organic Chemistry 2003; 68(14):5731-5734.
[33]Avdagic A, Hamersak Z. Preparing pregabalin comprises:reacting pentanedioic acid compound with azide compound, converting the product to isocyanatomethyl-hexanoic acid compound followed by reacting with allyl alcohol; and splitting urethane and ester function. Pliva Istrazivanje Razvoj Doo; Mcleish N a M; Pliva Hrvatska Doo,2008.
[34]Huckabee BK, Sobieray DM, Methods of making (S)-3-(aminomethyl)-5-methyl-hexanoic acid. WO9638405-A1,1996.
[35]Zhang G Yang X, Ma Y, Shi S, Duan L, Zhu Y, Novel 3-isobutyl glutaryl imine, useful as intermediate for preparing pregabalin used in treating epilepsy and neuropathic pain. WO2006136087-A1, 2007.
[36]Grote TM, Huckabee BK, Mulhern T, Bieray DM, Titus RD, Sobieray DM, (S)-3-(Aminomethyl)-5-methyl hexanoic acid prepn.-useful as anticonvulsant, in process that does not require expensive reagents or low temps. WO9640617-A1, 1996.
[37]Hu S, Martinez CA, Tao J, et al.. Preparation of (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid involves either reacting substituted pyrrolidine compound with acid and water, reducing cyano moiety and decarboxylating amino moiety or reducing cyano moiety. US2005283023-A1,2006.
[38]Martinez CA, Hu S, Dumond Y, Tao J, Kelleher P, Tully L. Development of a chemoenzymatic manufacturing process for pregabalin. Organic Process Research & Development 2008; 12(3):392-398.
[39]Burns MP, Weaver JK, Wong JW, John WW, Justin KW, Michel PB, Preparation of cyanocarboxylic acid, useful to synthesize e.g. pregabalin, comprises contacting succinonitrile with an enzyme catalyst having nitrilase activity in a reaction medium and recovering (3S) isomer. WO2005100580-A1,2005.
[40]Hedvati L, Fishman A. the use of enzymatic resolution for the preparation of intermediates of pregabalin. WO2007143113-A2,2007.
[41]Margolin AL. Enzymes in the synthesis of chiral drugs. Enzyme and Microbial Technology 1993; 15(4):266-280.
[42]Santaniello E, Ferraboschi P, Grisenti P, Manzocchi A. The biocatalytic approach to the preparation of enantiomerically pure chiral building-blocks. Chemical Reviews 1992; 92(5):1071-1140.
[43]Faber K, Franssen MCR. Prosects fro the increased application of biocatalysis in organic transformations. Trends in Biotechnology 1993; 11(11):461-470.
[44]王婷,吴坚平,杨立荣等.普瑞巴林手性中间体的合成工艺研究.应用化学2010；39(2)：183-188.
[45]Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST:a new generation of protein database search programs. Nucleic Acids Research 1997; 25(17):3389-3402.
[46]Chen CS, Fujimoto Y, Girdaukas G, Sih CJ. Quantitative-analyses of biochemical kinetic resolutions of enantiomers. Journal of the American Chemical Society 1982; 104(25):7294-7299.
[47]Tang XJ, He GQ, Chen QH, Zhang XY, Ali MAM. Medium optimization for the production of thermal stable beta-glucanase by Bacillus subtilis ZJF-1A5 using response surface methodology. Bioresour Technol 2004; 93(2):175-181.
[48]Jia B, Jin ZH, Mei LH. Medium optimization based on statistical methodologies for pristinamycins production by Streptomyces pristinaespiralis. Applied Biochemistry and Biotechnology 2008; 144(2):133-143.
[49]Ivancic M, Santek B, Novak S, Maric V. Fermentative bioconversion in a horizontal rotating tubular bioreactor. Process Biochemistry 2004; 39(8):995-1000.
[50]Shimoni E, Ravid U, Shoham Y. Isolation of a Bacillus sp capable of transforming isoeugenol to vanillin. Journal of Biotechnology 2000; 78(1):1-9.
[51]Hurh B, Ohshima M, Yamane T, Nagasawa T. Microbial-production of 6-hydroxynicotinic acid, an important building, block for the synthesis of modern insecticides. Journal of Fermentation and Bioengineering 1994; 77(4):382-385.
[52]Nagasawa T, Hurh B, Yamane T. Production of 6-hydroxynicotinic acid from nicotinic-acid by resting cells of pseudomonas-fluorescens TN5. Bioscience Biotechnology and Biochemistry 1994; 58(4):665-668.
[53]Lin SF, Chiou CM, Tsai YC. Effect of Triton X-100 on alkaline lipase production by pseudomonas pseudoalcaligenes F-111. Biotechnology Letters 1995; 17(9): 959-962.
[54]Liu YY, Xu JH, Hu Y. Enhancing effect of Tween-80 on lipase performance in enantioselective hydrolysis of ketoprofen ester. Journal of Molecular Catalysis B-Enzymatic 2000; 10(5):523-529.
[55]Lie F, Chen YZ, Wang ZS, Li Z. Enantioselective benzylic hydroxylation of indan and tetralin with Pseudomonas monteilii TA-5. Tetrahedron-Asymmetry 2009; 20(10): 1206-1211.
[56]Helisto P, Korpela T. Effects of detergents on activity of microbial lipases as measured by the nitrophenyl alkanoate esters method. Enzyme and Microbial Technology 1998; 23(1-2):113-117.
[57]Misiorow.Rl. Wells MA. Activity of phospholipase A2 in reversed micelles of phosphatidylcholine in diethyl-ether-Effect of water and cations. Biochemistry 1974; 13(24):4921-4927.
[58]Edwards K, Chan RYS, Sawyer WH. Interactions between fatty-acids and lipoprotein-lipase-Specific binding and complex-formation. Biochemistry 1994; 33(45):13304-13311.
[59]Pieterso.Wa, Vidal JC, Volwerk JJ, Haas GHD. Zymogen-catalyzed hydrolysis of monomeric substrates and presence of a recognition site for lipid-water interfaces in phospholipase-A2. Biochemistry 1974; 13(7):1455-1460.
[60]Mozaffar Z, Weete JD, Dute R. Influence of surfactants on an extracellular lipase from Pythium ultimum. J Am Oil Chem Soc 1994; 71(1):75-79.
[61]Xia J, Chen X, Nnanna IA. Activity and stability ofPenicillium cyclopium lipase in surfactant and detergent solutions. J Am Oil Chem Soc 1996; 73(1):115-120.
[62]Terstappen GC, Ramelmeier RA, Kula MR. Protein partitioning in detergent-based aqueous two-phase systems. J Biotechnol 1993; 28(2-3):263-275.
[63]Li JHY, Zuzack JS. Kau ST. Effects of detergents on sodium transport in toad urinary bladder. J Pharm Exp 1986; 238(2):415-421.
[64]Kosugi Y, Kamibayashi A. Thermostable lipase from Pseudomonas sp.:cultural conditions and properties of the crude enzyme. J Ferment Technol 1971; 59:968.
[65]赵玉巧,许建和.不动杆菌静息细胞催化拆分外消旋环戊酮醇乙酸酯反应条件的优化.催化学报2003；24(8)：613-618.
[66]王洪祚,刘世勇.酶和细胞的固定化.化学通报1997；2：22-27.
[67]Vassilev N, Vassileva M, Fenice M, Federici F. Immobilized cell technology applied in solubilization of insoluble inorganic (rock) phosphates and P plant acquisition. Bioresource Technology 2001; 79(3):263-271.
[68]李冀新,张超,高虹.固定化细胞技术应用研究进展.化学与生物工程2006；23(6)：5-7.
[69]杨文英,董学畅.细胞固定化及其在工业中的应用.云南民族学院学报(自然
科学版)2001；10(3)：406-410.
[70]Junter GA, Coquet L, Vilain S, al e. Immobilized-cell physiology:current data and the potentialities of proteomics. Enzyme Microb Tech 2002; 31(3):201-212.
[71]Jacobson BS, Branton D. Plasma membrane:Rapid Isolation and Exposure of the Cytoplasmic Surface by Use of Positively Charged Beads. Science 1977; 195(4275): 302-304.
[72]Arkles BC, Miller AS, Brinigar WS. Whole cell and cell organelle immobilizationon siliceous surfaces. Midl Macromol Monogr 1980; (7):363-375.
[73]肖美燕,徐尔尼,陈志文.包埋法固定化细胞技术的研究进展.食品科学2003；24(4)：158-161.
[74]Zeng CM, Zhang YX, Lu LL, al e. Immobilization of human red cells in gel particles for chromatographic activity studies of the glucose transporter Glut1. Biochimica et Biophysica Acta 1997; 1325(1):91-98.
[75]Nagadomi H, Kitamura T, Watanabe M, al e. Simultaneous removal of chemical oxygen demand(COD), phosphate, nitrate and H2S in the synthetic sewage wastewater using porous ceramic immobilized photosynthetic bacteria. Biotechnol Lett 2000; 22(17):1369-1374.
[76]Bonin P, Rontani JF, Bordenave L. Metabolic differences between attached and free-living marine bacteria:inadequacy of liquid cultures for describing in situbacterial activity. FEMS Microbiol Lett 2001; 194(1):111-119.
[77]Manseld J, Schellenberger A, Rimbach J. Application of polystyrene-bound invertase to continuous sucrose hydrolysis on pilot scale. Biotechnol Bioeng 1992; 40(9):997-1003.
[78]杨秀山,李军,田沈等.固定化甲烷八叠球茵及处理高浓度有机废水的研究.环境科学学报2003；23(2)：282-284.
[79]宋秀兰,田建民,麻静文.固定化胶质红环茵在好氧条件下降分解吲哚的研究.环境科学学报2001；21(4)：510-512.
[80]李超敏,韩梅,张良等.细胞固定化技术-海藻酸钠包埋法的研究进展.安徽农业科学2006；34(7)：1281-1284.
[81]徐鑫煤,陈英文,沈树宝.壳聚糖固定化酶和细胞研究新进展.化工科技2006；14(1)：54-57.
[82]Chang CC, Tseng SK. Immobilization of Alcaligenes eutrophus using PVA cross-linked with sodium nitrate. Biotechnology Techniques 1998; 12(12):865-868.
[83]Mallouchos A, Reppa P, Aggelis G, al e. Grape skins as a natural support for yeast immobilization. Biotech Lett 2002; 24(16):1331-1335.
[84]王克明.复合栽体固定化细胞红曲色素发酵条件的研究.中国酿造2005；(6)：9-12.
[85]Casson D, Emery AN. On the elimination of artefactual effects in assessing the structure of calcium alginate cell immobilization gels. Enzyme Microbiol Technol 1987; (9):102-106.
[86]Dervakos GA, Webb C. On the merits of viable-cell immobilization. Biotech Adv 1991; (9):559-612.
[87]刘阳,曹军卫,翟超.米曲霉菌体细胞固定化及DL-蛋氨酸的光学拆分.武汉大学学报(自然科学版)2000；46(6)：769-772.
[88]Baillez C. Immobilization of botryococcus braunnii in alginate influence on chlorophyll content photasynthetic activity and degenration during batch culture. Applied Microbiology and Biotechnology 1986; (23):361-366.
[89]蒋宇红,黄霞,俞毓馨.几种固定化细胞载体的比较.环境科学1993；14(2)：11-15.
[90]王雪梅,于明锐,谭天伟.海藻酸钠复合载体固定化细胞拆分D,L-泛解酸内酯.北京化工大学学报2006；33(3)：28-32.
[91]Cunha A, Deshusses JS, Webster MA, al e. Use of PVA-gel immobilized cells:a new strategy for biotechnological production of xylitol from sugarcane bagasse hydrolysate. Semina:Ciencias Agrarias 2005; 26(1):61-70.
[92]周少奇,周吉林.生物脱氮新技术研究进展.环境污染治理技术与设备2000；1(6)：11-19.
[93]Hyungseok Y, AHN KH. Nitrogen removal from synthetic wastewater by simultaneous nitrification and denitrification (SND) vianitrite in an interm ittently aerated reactor. Waters 1999; 33(1):145-154.
[94]赵兴利.固定化硝化菌去除废水中氨氮工艺的研究.环境科学2006；20(1)：39-42.
[95]谭佑铭,罗启芳.固定化反硝化细菌去除水中硝酸盐氮的研究.环境与健康杂志2001；18(6)：371-373.
[96]Elizaveta A, Muller D, Bardakivsdaya KI, al e. High-porosity activated carbon as a possible matrix for native DNA and Dextran-sulfate immoblization. Artificial Cells, Blood Substitutes, and Biotechnology 2004; 32(4):529-537.
[97]王建龙editor,生物固定化技术与水污染控制.北京：科学出版社,2002.
[2]Bryans JS, Wustrow DJ.3-substituted GABA analogs with central nervous system activity:a review. Med Res Rev 1999; 19(2):149-177.
[3]Pellock JM. Treatment of epilepsy in the new millennium. Pharmacotherapy 2000; 20(8 Pt2):129S-138S.
[4]Singh D, Kennedy DH. The use of gabapentin for the treatment of postherpetic neuralgia. Clin Ther 2003;25(3):852-889.
[5]陈敖,张建军.普瑞巴林的合成.中国医药工业杂志2004；35(4)：195-196.
[6]陈敖,张建军.新药普瑞巴林的合成.精细与专用化学品2005；13(10)：14-17.
[7]李晓东,须眉GABA受体激活剂：普瑞巴林(pregabalin)世界临床药物2006；27(3)：186-187.
[8]陈宝泉,李彩文,史艳萍,卢学磊,麻静.普瑞巴林的药理作用及临床评价.中国新药与临床杂志2010；29(1)：11-14.
[9]崔露阳.抗癫痫药物市场格局浅析.世界临床药物2005；26(3)：188-191.
[10]江正祥.抗癫痫药物市场发展趋势.世界临床药物2010；31(8)：510-513.
[11]伍光辉,潘天伟.抗癫痫药物治疗精神病研究进展Internal Medicine China 2008; 3(6):924-926.
[12]洪刚,章江生,王琳辉.抗癫痫药物研究进展.中国临床药理学与治疗学2005；10(11)：1201-1209.
[13]Warner G, Figgitt DP. Pregabalin-As adjunctive treatment of partial seizures. Cns Drugs 2005; 19(3):265-272.
[14]Simko J, Horacek J, Waberzinek G. Severe hypothyroidism as a complication of anticonvulsant treatment. Epilepsia 2004; 45(3):292-293.
[15]Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine 1999; 159(16):1931-1937.
[16]Huang CW, Huang CC. Wu SN. The opening effect of pregabalin on ATP-sensitive potassium channels in differentiated hippocampal neuron-derived HI9-7 cells. Epilepsia 2006; 47(4):720-726.
[17]Stahl SM. Anticonvulsants as anxiolytics, part 2:pregabalin and gabapentin as α2δ ligands at voltage-gated calcium channels. Clin Psychiatry 2004; 65(4):460-461.
[18]Joshi I, Taylor CP. Pregabalin action at a model synase; binding to presynaptic calcium channel alpha2-delta subunit reduces neurotransmission in mice. Eur J Pharmacol 2006; 553(1-3):82-88.
[19]Belliotti TR. Capiris T, Ekhato IV, al. e. Structure-activity relationships of pregabalin and analogues that target the alpha2-delta protein. J Med Chem 2005; 48(7):2294-2307.
[20]Galluzzi KE. Managing neuropathic pain. J Am Osteopath Assoc 2007; 107(10 Suppl 60):ES39-ES48.
[21]Aiello EC. Thomson A. vera 1M. ai e. Cost-effectiveness of pregabalin and other acid-on amiepileptic drug therapies in. patiems with refracton partial epilepsy in Aroentina. vaiue Health 200-:10:89.
[22]Herranz JL, Argumosa A. Rejas J, al e. Model-based evaluation of the cost-effectiveness of pregabalin. levetiracetam and generic gabapentin versus standard therapy as an add-on antiepileptic therapy in patients with refractory epilepsy:a Spanish perspective. Epilepsia 2005; 46(Suppl 6):S115-S116.
[23]Rosenstock J, Michael TB, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy:a double-blind, placebo-controlled trial. Pain 2004; 110(3):628-638.
[24]陈志青,徐俊冕.抗癫痫药物用于焦虑障碍治疗的评价.世界临床药物2005；26(12)：747-753.
[25]Suljic E. Alajbegovic A, Kucukalic A, Loncarevic N. [Comorbid depression in patients with epilepsy treated with single and multiple drug therapy]. Med Arh 2003; 57(5-6 Suppl 1):45-46.
[26]Leppik LE, Bergey GK, Ramsay RE, et al. Advances in antiepileptic drug treatments-A rational basis for selecting drugs for older patients with epilepsy. Geriatrics 2004; 59(12):14-+.
[27]赵倩,李讳亮,肖学凤.治疗神经性疼痛新药-普瑞巴林.天津药学2007;19(12)：53-55.
[28]Evans DA, Ennis MD, Mathre DJ. Asymmetric alkylation reactions of chiral imide enolates-A Practical approach to the enantioselective synthesis of alpha-substituted carboxylic-acid derivatives. J Am Chem Soc 1982; 104(6): 1737-1739.
[29]Yuen PW, Kanter GD, Taylor CP, Vartanian MG. Enantioselective synthesis of PD144723-A Potent stereospecific anticonvulsant. Bioorganic & Medicinal Chemistry Letters 1994; 4(6):823-826.
[30]Hoekstra MS, Sobieray DM, Schwindt MA, et al. Chemical development of CI-1008, an enantiomerically pure anticonvulsant. Organic Process Research & Development 1997; 1(1):26-38.
[31]Sammis GM, Jacobsen EN. Highly enantioselective, catalytic conjugate addition of cyanide to alpha,beta-unsaturated Imides. J Am Chem Soc 2003; 125(15): 4442-4443.
[32]Burk MJ, de Koning PD, Grote TM, et al. An enantioselective synthesis of (S)-(+)-3-aminomethyl-5-methylhexanoic acid via asymmetric hydrogenation. Journal of Organic Chemistry 2003; 68(14):5731-5734.
[33]Avdagic A, Hamersak Z. Preparing pregabalin comprises:reacting pentanedioic acid compound with azide compound, converting the product to isocyanatomethyl-hexanoic acid compound followed by reacting with allyl alcohol; and splitting urethane and ester function. Pliva Istrazivanje Razvoj Doo; Mcleish N a M; Pliva Hrvatska Doo,2008.
[34]Huckabee BK, Sobieray DM, Methods of making (S)-3-(aminomethyl)-5-methyl-hexanoic acid. WO9638405-A1,1996.
[35]Zhang G Yang X, Ma Y, Shi S, Duan L, Zhu Y, Novel 3-isobutyl glutaryl imine, useful as intermediate for preparing pregabalin used in treating epilepsy and neuropathic pain. WO2006136087-A1, 2007.
[36]Grote TM, Huckabee BK, Mulhern T, Bieray DM, Titus RD, Sobieray DM, (S)-3-(Aminomethyl)-5-methyl hexanoic acid prepn.-useful as anticonvulsant, in process that does not require expensive reagents or low temps. WO9640617-A1, 1996.
[37]Hu S, Martinez CA, Tao J, et al.. Preparation of (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid involves either reacting substituted pyrrolidine compound with acid and water, reducing cyano moiety and decarboxylating amino moiety or reducing cyano moiety. US2005283023-A1,2006.
[38]Martinez CA, Hu S, Dumond Y, Tao J, Kelleher P, Tully L. Development of a chemoenzymatic manufacturing process for pregabalin. Organic Process Research & Development 2008; 12(3):392-398.
[39]Burns MP, Weaver JK, Wong JW, John WW, Justin KW, Michel PB, Preparation of cyanocarboxylic acid, useful to synthesize e.g. pregabalin, comprises contacting succinonitrile with an enzyme catalyst having nitrilase activity in a reaction medium and recovering (3S) isomer. WO2005100580-A1,2005.
[40]Hedvati L, Fishman A. the use of enzymatic resolution for the preparation of intermediates of pregabalin. WO2007143113-A2,2007.
[41]Margolin AL. Enzymes in the synthesis of chiral drugs. Enzyme and Microbial Technology 1993; 15(4):266-280.
[42]Santaniello E, Ferraboschi P, Grisenti P, Manzocchi A. The biocatalytic approach to the preparation of enantiomerically pure chiral building-blocks. Chemical Reviews 1992; 92(5):1071-1140.
[43]Faber K, Franssen MCR. Prosects fro the increased application of biocatalysis in organic transformations. Trends in Biotechnology 1993; 11(11):461-470.
[44]王婷,吴坚平,杨立荣等.普瑞巴林手性中间体的合成工艺研究.应用化学2010；39(2)：183-188.
[45]Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST:a new generation of protein database search programs. Nucleic Acids Research 1997; 25(17):3389-3402.
[46]Chen CS, Fujimoto Y, Girdaukas G, Sih CJ. Quantitative-analyses of biochemical kinetic resolutions of enantiomers. Journal of the American Chemical Society 1982; 104(25):7294-7299.
[47]Tang XJ, He GQ, Chen QH, Zhang XY, Ali MAM. Medium optimization for the production of thermal stable beta-glucanase by Bacillus subtilis ZJF-1A5 using response surface methodology. Bioresour Technol 2004; 93(2):175-181.
[48]Jia B, Jin ZH, Mei LH. Medium optimization based on statistical methodologies for pristinamycins production by Streptomyces pristinaespiralis. Applied Biochemistry and Biotechnology 2008; 144(2):133-143.
[49]Ivancic M, Santek B, Novak S, Maric V. Fermentative bioconversion in a horizontal rotating tubular bioreactor. Process Biochemistry 2004; 39(8):995-1000.
[50]Shimoni E, Ravid U, Shoham Y. Isolation of a Bacillus sp capable of transforming isoeugenol to vanillin. Journal of Biotechnology 2000; 78(1):1-9.
[51]Hurh B, Ohshima M, Yamane T, Nagasawa T. Microbial-production of 6-hydroxynicotinic acid, an important building, block for the synthesis of modern insecticides. Journal of Fermentation and Bioengineering 1994; 77(4):382-385.
[52]Nagasawa T, Hurh B, Yamane T. Production of 6-hydroxynicotinic acid from nicotinic-acid by resting cells of pseudomonas-fluorescens TN5. Bioscience Biotechnology and Biochemistry 1994; 58(4):665-668.
[53]Lin SF, Chiou CM, Tsai YC. Effect of Triton X-100 on alkaline lipase production by pseudomonas pseudoalcaligenes F-111. Biotechnology Letters 1995; 17(9): 959-962.
[54]Liu YY, Xu JH, Hu Y. Enhancing effect of Tween-80 on lipase performance in enantioselective hydrolysis of ketoprofen ester. Journal of Molecular Catalysis B-Enzymatic 2000; 10(5):523-529.
[55]Lie F, Chen YZ, Wang ZS, Li Z. Enantioselective benzylic hydroxylation of indan and tetralin with Pseudomonas monteilii TA-5. Tetrahedron-Asymmetry 2009; 20(10): 1206-1211.
[56]Helisto P, Korpela T. Effects of detergents on activity of microbial lipases as measured by the nitrophenyl alkanoate esters method. Enzyme and Microbial Technology 1998; 23(1-2):113-117.
[57]Misiorow.Rl. Wells MA. Activity of phospholipase A2 in reversed micelles of phosphatidylcholine in diethyl-ether-Effect of water and cations. Biochemistry 1974; 13(24):4921-4927.
[58]Edwards K, Chan RYS, Sawyer WH. Interactions between fatty-acids and lipoprotein-lipase-Specific binding and complex-formation. Biochemistry 1994; 33(45):13304-13311.
[59]Pieterso.Wa, Vidal JC, Volwerk JJ, Haas GHD. Zymogen-catalyzed hydrolysis of monomeric substrates and presence of a recognition site for lipid-water interfaces in phospholipase-A2. Biochemistry 1974; 13(7):1455-1460.
[60]Mozaffar Z, Weete JD, Dute R. Influence of surfactants on an extracellular lipase from Pythium ultimum. J Am Oil Chem Soc 1994; 71(1):75-79.
[61]Xia J, Chen X, Nnanna IA. Activity and stability ofPenicillium cyclopium lipase in surfactant and detergent solutions. J Am Oil Chem Soc 1996; 73(1):115-120.
[62]Terstappen GC, Ramelmeier RA, Kula MR. Protein partitioning in detergent-based aqueous two-phase systems. J Biotechnol 1993; 28(2-3):263-275.
[63]Li JHY, Zuzack JS. Kau ST. Effects of detergents on sodium transport in toad urinary bladder. J Pharm Exp 1986; 238(2):415-421.
[64]Kosugi Y, Kamibayashi A. Thermostable lipase from Pseudomonas sp.:cultural conditions and properties of the crude enzyme. J Ferment Technol 1971; 59:968.
[65]赵玉巧,许建和.不动杆菌静息细胞催化拆分外消旋环戊酮醇乙酸酯反应条件的优化.催化学报2003；24(8)：613-618.
[66]王洪祚,刘世勇.酶和细胞的固定化.化学通报1997；2：22-27.
[67]Vassilev N, Vassileva M, Fenice M, Federici F. Immobilized cell technology applied in solubilization of insoluble inorganic (rock) phosphates and P plant acquisition. Bioresource Technology 2001; 79(3):263-271.
[68]李冀新,张超,高虹.固定化细胞技术应用研究进展.化学与生物工程2006；23(6)：5-7.
[69]杨文英,董学畅.细胞固定化及其在工业中的应用.云南民族学院学报(自然
科学版)2001；10(3)：406-410.
[70]Junter GA, Coquet L, Vilain S, al e. Immobilized-cell physiology:current data and the potentialities of proteomics. Enzyme Microb Tech 2002; 31(3):201-212.
[71]Jacobson BS, Branton D. Plasma membrane:Rapid Isolation and Exposure of the Cytoplasmic Surface by Use of Positively Charged Beads. Science 1977; 195(4275): 302-304.
[72]Arkles BC, Miller AS, Brinigar WS. Whole cell and cell organelle immobilizationon siliceous surfaces. Midl Macromol Monogr 1980; (7):363-375.
[73]肖美燕,徐尔尼,陈志文.包埋法固定化细胞技术的研究进展.食品科学2003；24(4)：158-161.
[74]Zeng CM, Zhang YX, Lu LL, al e. Immobilization of human red cells in gel particles for chromatographic activity studies of the glucose transporter Glut1. Biochimica et Biophysica Acta 1997; 1325(1):91-98.
[75]Nagadomi H, Kitamura T, Watanabe M, al e. Simultaneous removal of chemical oxygen demand(COD), phosphate, nitrate and H2S in the synthetic sewage wastewater using porous ceramic immobilized photosynthetic bacteria. Biotechnol Lett 2000; 22(17):1369-1374.
[76]Bonin P, Rontani JF, Bordenave L. Metabolic differences between attached and free-living marine bacteria:inadequacy of liquid cultures for describing in situbacterial activity. FEMS Microbiol Lett 2001; 194(1):111-119.
[77]Manseld J, Schellenberger A, Rimbach J. Application of polystyrene-bound invertase to continuous sucrose hydrolysis on pilot scale. Biotechnol Bioeng 1992; 40(9):997-1003.
[78]杨秀山,李军,田沈等.固定化甲烷八叠球茵及处理高浓度有机废水的研究.环境科学学报2003；23(2)：282-284.
[79]宋秀兰,田建民,麻静文.固定化胶质红环茵在好氧条件下降分解吲哚的研究.环境科学学报2001；21(4)：510-512.
[80]李超敏,韩梅,张良等.细胞固定化技术-海藻酸钠包埋法的研究进展.安徽农业科学2006；34(7)：1281-1284.
[81]徐鑫煤,陈英文,沈树宝.壳聚糖固定化酶和细胞研究新进展.化工科技2006；14(1)：54-57.
[82]Chang CC, Tseng SK. Immobilization of Alcaligenes eutrophus using PVA cross-linked with sodium nitrate. Biotechnology Techniques 1998; 12(12):865-868.
[83]Mallouchos A, Reppa P, Aggelis G, al e. Grape skins as a natural support for yeast immobilization. Biotech Lett 2002; 24(16):1331-1335.
[84]王克明.复合栽体固定化细胞红曲色素发酵条件的研究.中国酿造2005；(6)：9-12.
[85]Casson D, Emery AN. On the elimination of artefactual effects in assessing the structure of calcium alginate cell immobilization gels. Enzyme Microbiol Technol 1987; (9):102-106.
[86]Dervakos GA, Webb C. On the merits of viable-cell immobilization. Biotech Adv 1991; (9):559-612.
[87]刘阳,曹军卫,翟超.米曲霉菌体细胞固定化及DL-蛋氨酸的光学拆分.武汉大学学报(自然科学版)2000；46(6)：769-772.
[88]Baillez C. Immobilization of botryococcus braunnii in alginate influence on chlorophyll content photasynthetic activity and degenration during batch culture. Applied Microbiology and Biotechnology 1986; (23):361-366.
[89]蒋宇红,黄霞,俞毓馨.几种固定化细胞载体的比较.环境科学1993；14(2)：11-15.
[90]王雪梅,于明锐,谭天伟.海藻酸钠复合载体固定化细胞拆分D,L-泛解酸内酯.北京化工大学学报2006；33(3)：28-32.
[91]Cunha A, Deshusses JS, Webster MA, al e. Use of PVA-gel immobilized cells:a new strategy for biotechnological production of xylitol from sugarcane bagasse hydrolysate. Semina:Ciencias Agrarias 2005; 26(1):61-70.
[92]周少奇,周吉林.生物脱氮新技术研究进展.环境污染治理技术与设备2000；1(6)：11-19.
[93]Hyungseok Y, AHN KH. Nitrogen removal from synthetic wastewater by simultaneous nitrification and denitrification (SND) vianitrite in an interm ittently aerated reactor. Waters 1999; 33(1):145-154.
[94]赵兴利.固定化硝化菌去除废水中氨氮工艺的研究.环境科学2006；20(1)：39-42.
[95]谭佑铭,罗启芳.固定化反硝化细菌去除水中硝酸盐氮的研究.环境与健康杂志2001；18(6)：371-373.
[96]Elizaveta A, Muller D, Bardakivsdaya KI, al e. High-porosity activated carbon as a possible matrix for native DNA and Dextran-sulfate immoblization. Artificial Cells, Blood Substitutes, and Biotechnology 2004; 32(4):529-537.
[97]王建龙editor,生物固定化技术与水污染控制.北京：科学出版社,2002.